SCHEMBL57060

SCHEMBL57060

NCCN(Cc1ccccn1)Cc1ccccn1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
LIN28A Q9H9Z2 1/20 0.78
TDP1 Q9NUW8 1/20 0.78
HRH1 P35367 2/20 0.57
CXCR4 P61073 3/20 0.49
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
KCNA5 P22460 1/20 0.46
KMT2A Q03164 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
TERT O14746 1/20 0.43
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407086 1.00 MAPT (0.78) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL814039 0.96 MAPT (0.71) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL11471516 0.90 TDP1 (0.62) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL17119746 0.90 TDP1 (0.62) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL8527380 0.89 MAPT (0.72) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL8508012 0.88 SMN1; SMN2 (0.61) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL29427509 0.88 TDP1 (1.00) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL231092 0.88 TDP1 (1.00) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL10261442 0.87 MAPT (0.70) MAPTSMN1; SMN2LIN28ATDP1HRH1
SCHEMBL28051459 0.87 TDP1 (0.59) MAPTSMN1; SMN2LIN28ATDP1HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210220482-A1 MITOCHONDRIAL COPPER DEPLETION REPROGRAMS THE METABOLISM OF TRIPLE NEGATIVE BREAST CANCER THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-07-22 US claimed
EP-2744771-B1 C-HALOGEN BOND FORMATION UNIV PRINCETON (US) 2020-10-21 EP claimed
CN-109641835-A Method for producing carbamate 国立研究开发法人产业技术综合研究所 2019-04-16 CN claimed
US-7563897-B2 Naphthalene diimide-Zn(II) complex having selectivity for pyrophosphate, preparation method thereof and detecting method of pyrophosphate using the same EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2009-07-21 US claimed
WO-2008130092-A1 NAPHTHALENE DIIMIDE-ZN(II) COMPLEX HAVING SELECTIVITY FOR PYROPHOSPHATE, PREPARATION METHOD THEREOF AND DETECTING METHOD OF PYROPHOSPHATE USING THE SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2008-10-30 WO claimed
US-20080261196-A1 NAPHTHALENE DIIMIDE-ZN(II) COMPLEX HAVING SELECTIVITY FOR PYROPHOSPHATE, PREPARATION METHOD THEREOF AND DETECTING METHOD OF PYROPHOSPHATE USING THE SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2008-10-23 US claimed
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 US disclosed
EP-4644387-A2 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2025-11-05 EP disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250195647-A1 ANTI-alpha-V-beta-8 INTEGRIN ANTIBODIES AND USES THEREOF CORBUS PHARMACEUTICALS, INC. 2025-06-19 US disclosed
US-20250179024-A1 AMYLOID AND ASSOCIATED PATHOLOGY MODULATORS AND METHODS THEREOF JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) 2025-06-05 US disclosed
EP-3518973-B1 NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY UNIV CALIFORNIA (US) 2025-04-30 EP disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
US-20070191607-A1 Catalyst composition EXXONMOBIL CHEMICAL PATENTS INC. 2007-08-16 US disclosed
US-7217675-B2 Catalyst composition EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-05-15 US disclosed
US-20040242893-A1 Catalyst composition EXXONMOBIL CHEMICAL PATENTS INC. 2004-12-02 US disclosed
EP-1268731-B1 BLEACHING AND DYE TRANSFER INHIBITING COMPOSITION AND METHOD FOR STAIN BLEACHING OF LAUNDRY FABRICS UNILEVER PLC (GB) 2003-12-17 EP disclosed
US-20020010121-A1 Bleaching and dye transfer inhibiting composition and method for laundry fabrics UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-01-24 US disclosed
EP-1001009-A1 Bleach and oxidation catalyst UNILEVER PLC (GB) 2000-05-17 EP disclosed
EP-0755925-B1 N,N'-di(aralkyl)-N,N'-di(2-azaaralkyl)alkylene-diamine derivatives and their use in pharmaceutical and cosmetic compositions OREAL (FR) 1998-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179024-A1 AMYLOID AND ASSOCIATED PATHOLOGY MODULATORS AND METHODS THEREOF APP, NFE2L2, BACE1 MAPT 17/4885SMN1; SMN2 676/4885LIN28A 4774/4885
US-20080261196-A1 NAPHTHALENE DIIMIDE-ZN(II) COMPLEX HAVING SELECTIVITY FOR PYROPHOSPHATE, PREPARATION METHOD THEREOF AND DETECTING METHOD OF PYROPHOSPHATE USING THE SAME PPIP5K2, ITPA, PPA1 MAPT 4076/4885SMN1; SMN2 4524/4885LIN28A 4807/4885
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS MAPT 4269/4885SMN1; SMN2 4001/4885LIN28A 1552/4885
US-20040242893-A1 Catalyst composition MLX, BMX, CDYL MAPT 1633/4885SMN1; SMN2 1979/4885LIN28A 686/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS MAPT 2071/4885SMN1; SMN2 1576/4885LIN28A 891/4885
US-20070191607-A1 Catalyst composition MLX, LMNB2, TPX2 MAPT 1784/4885SMN1; SMN2 2436/4885LIN28A 493/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 MAPT 2371/4885SMN1; SMN2 3909/4885LIN28A 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.